How India Exports Cytarabine to the World

In the United States, cytarabine is approved for the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia, and chronic myelocytic leukemia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for cytarabine, indicating a competitive generic market. The absence of current import alerts or significant regulatory actions suggests a stable regulatory environment for cytarabine imports into the U.S. Given the substantial number of Indian exporters, this stability is crucial for maintaining consistent supply chains.

Within the European Union, cytarabine is subject to the European Medicines Agency's (EMA) centralized marketing authorization process. A notable development occurred in July 2018 when the marketing authorization for DepoCyte, a liposomal formulation of cytarabine, was withdrawn at the request of the marketing authorization holder, Pacira Ltd, due to commercial reasons. This withdrawal underscores the dynamic nature of the regulatory landscape. Manufacturers exporting to the EU and UK must adhere to Good Manufacturing Practice (GMP) standards as outlined by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Cytarabine is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its critical role in treating priority health conditions globally. This inclusion emphasizes the necessity for its availability and affordability worldwide. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential to ensure the quality and efficacy of cytarabine formulations.

In India, cytarabine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, cytarabine is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national and international regulations.

The primary patents for cytarabine have expired, facilitating the production and export of generic versions by multiple manufacturers. This has led to increased competition and more affordable pricing in the global market.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming cytarabine's inclusion due to its continued relevance in treating hematological malignancies. This underscores the ongoing global recognition of cytarabine's importance in oncology.

In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, which includes cytarabine, highlighting its critical role in treating priority health conditions globally. (who.int)

In January 2026, the WHO released a fact sheet on essential medicines, emphasizing the importance of medicines like cytarabine in treating priority health-care needs and their inclusion in the WHO Model List of Essential Medicines. (who.int)

These developments reflect the dynamic nature of the pharmaceutical industry and the importance of staying informed about regulatory changes and market trends to ensure compliance and strategic positioning in the global market.

Cytarabine, a critical chemotherapeutic agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

The reliance on Chinese KSMs introduces substantial risks to the supply chain. Any disruptions in China's production capabilities—be it due to environmental regulations, geopolitical tensions, or other factors—can lead to shortages and increased costs for APIs. For instance, in July 2018, shutdowns of Chinese chemical plants due to environmental concerns led to significant supply constraints and price hikes for Indian pharmaceutical manufacturers.

Our proprietary trade data indicates that the top five Indian exporters account for 77.2% of Cytarabine exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 47.6%. This high concentration among a few suppliers poses a significant risk; any operational disruptions within these key companies could severely impact global Cytarabine availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. Notably, in October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, the effectiveness of the PLI scheme in diversifying Cytarabine's supplier base remains to be seen.

Recent geopolitical tensions have further exacerbated supply chain vulnerabilities. In February 2026, military conflicts in the Middle East led to the effective closure of the Strait of Hormuz, a critical maritime chokepoint. This disruption has significantly impacted the transportation of oil-based feedstocks essential for chemical and pharmaceutical manufacturing, leading to procurement delays and production cutbacks in Asia's chemical industry.

Additionally, the ongoing conflict has disrupted air transit routes, affecting the delivery of critical medicines, including cancer drugs, to the Gulf region. Pharmaceutical companies have been forced to reroute flights and seek alternative overland access, complicating logistics and potentially leading to shortages.

• Diversify KSM Sourcing: Identify and develop alternative suppliers for KSMs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Invest in domestic manufacturing capabilities for both APIs and KSMs, leveraging government initiatives like the PLI scheme to reduce import reliance.

• Expand Supplier Base: Encourage the entry of additional manufacturers into the Cytarabine market to decrease supplier concentration and mitigate single-source risks.

• Enhance Logistics Flexibility: Develop contingency plans for alternative shipping routes and transportation methods to navigate geopolitical disruptions effectively.

• Monitor Regulatory Developments: Stay informed about international regulatory changes and potential trade restrictions that could impact the pharmaceutical supply chain.

RISK_LEVEL: HIGH